IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Financial Insights Inc.

Financial Insights Inc. trimmed its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 48.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,912 shares of the medical research company’s stock after selling 1,801 shares during the quarter. Financial Insights Inc.’s holdings in IQVIA were worth $453,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Versant Capital Management Inc lifted its holdings in IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 110 shares during the last quarter. Opal Wealth Advisors LLC acquired a new position in shares of IQVIA in the second quarter worth about $27,000. Park Place Capital Corp acquired a new position in shares of IQVIA in the third quarter worth about $28,000. Itau Unibanco Holding S.A. acquired a new position in shares of IQVIA in the second quarter worth about $29,000. Finally, Riverview Trust Co acquired a new position in shares of IQVIA in the first quarter worth about $32,000. 89.62% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on IQV shares. Jefferies Financial Group cut shares of IQVIA from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $266.00 to $242.00 in a research report on Wednesday, July 24th. Argus upgraded shares of IQVIA to a “strong-buy” rating in a research report on Wednesday, July 31st. UBS Group lifted their price objective on shares of IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. JPMorgan Chase & Co. lifted their price objective on shares of IQVIA from $260.00 to $288.00 and gave the stock an “overweight” rating in a research report on Monday, August 5th. Finally, Barclays lowered their price objective on shares of IQVIA from $275.00 to $260.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 15th. Five investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $267.87.

IQVIA Trading Down 1.3 %

Shares of NYSE:IQV opened at $228.30 on Wednesday. The stock has a market capitalization of $41.62 billion, a PE ratio of 29.65, a P/E/G ratio of 2.26 and a beta of 1.49. IQVIA Holdings Inc. has a 1 year low of $167.42 and a 1 year high of $261.73. The firm has a fifty day moving average price of $238.87 and a 200 day moving average price of $230.93. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.57 by $0.07. The firm had revenue of $3.81 billion during the quarter, compared to analysts’ expectations of $3.79 billion. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. IQVIA’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same period in the prior year, the company posted $2.22 earnings per share. Analysts expect that IQVIA Holdings Inc. will post 10.25 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the sale, the insider now directly owns 19,536 shares in the company, valued at approximately $4,812,302.88. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.